Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada

First and only treatment of its kind for Canadians with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy – a rare and inherited disease OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics Inc.